secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-09-17T23:59:59+00:00
Accession:  0001655759-25-000147
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas and Pfizer to out-license vepdegestrant; cuts 15% workforce, authorizes $100M buyback
--------------------------------------------------------------------------------

- Plans to out-license vepdegestrant commercialization rights to a third party; PDUFA date June 5, 2026.
- Additional workforce reduction of 15%; expects $4.5M severance costs in Q3/Q4 2025.
- Total annual cost savings expected to exceed $100M compared to FY 2024, including prior actions.
- Board authorized up to $100M share repurchase program; funded by working capital, no time limit.
- Reaffirms cash runway into H2 2028; three Phase 1 PROTAC degraders (ARV-102, ARV-393, ARV-806) advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/0001655759-25-000147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvn-20250917.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer